# Kymera Therapeutics

**Canonical:** https://apis.io/providers/kymera-therapeutics/  
**Website:** https://www.kymeratx.com  
**APIs profiled:** 0

Kymera Therapeutics is a clinical-stage biopharmaceutical company headquartered at 500 North Beacon Street in Watertown, Massachusetts, pioneering targeted protein degradation as a way to build oral small-molecule medicines against targets that conventional inhibitors cannot reach. Rather than blocking a protein's activity, Kymera's degraders recruit the body's own protein-disposal machinery so that a binding event alone is sufficient to eliminate the disease-driving protein, an approach the company describes as a disease-agnostic modality. Its wholly-owned pipeline is led by KT-621, a once-daily oral STAT6 degrader in Phase 2 for Type 2 inflammatory diseases including atopic dermatitis, asthma, COPD and chronic spontaneous urticaria, and KT-579, a first-in-class oral IRF5 degrader in Phase 1 for lupus, Sjogren's syndrome and rheumatoid arthritis. Partnered programs include the oral IRAK4 degrader KT-485/SAR447971 with Sanofi and the CDK2 molecular glue degrader KT-200 with Gilead Sciences. Kymera publishes no public developer API or developer portal; this profile captures the company's public web, investor, patient and security surface for the API Evangelist network.

## Kin Score — 11.1 / 100 (emerging)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 11.1).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 2.6 |
| Developer Ergonomics | 4.8 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Kymera Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotech, Pharmaceuticals, Life Sciences, Drug Discovery, Targeted Protein Degradation, Immunology, Oncology, Clinical Trials, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/kymera-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.